Nestin promoter-driven ICP34.5 expression program (rQNestin34.5)

The Nestin promoter-driven ICP34.5 expression program is a genetic regulatory strategy designed for oncolytic virotherapy, specifically targeting malignant gliomas. It involves the insertion of the HSV-1 ICP34.5 gene, a critical factor for viral protein synthesis and replication, under the transcriptional control of the Nestin promoter (Kambara et al., 2005). Nestin is an intermediate filament protein that is highly expressed in neuroepithelial stem cells and glioblastoma cells but is absent in mature neurons, providing a basis for tumor-selective viral activity. In a typical infection, the host cell attempts to halt all protein synthesis via the PKR pathway to stop viral spread; however, ICP34.5 antagonizes this defense, allowing the virus to continue replicating (UniProt P0DPA2). By linking this 'replication switch' to the Nestin promoter, the resulting oncolytic virus (such as rQNestin34.5) can effectively destroy glioma cells while sparing the surrounding healthy brain tissue. This approach addresses the safety limitations of earlier oncolytic HSVs that completely deleted ICP34.5, which often resulted in significantly reduced therapeutic potency (Chiocca et al., 2020).

Other names

Nestin-driven ICP34.5rQNestin34.5 constructNestin-ICP34.5Nestin-driven gamma(1)34.5

The program utilizes the Nestin promoter to drive the expression of the Herpes Simplex Virus type 1 (HSV-1) ICP34.5 gene specifically within Nestin-expressing cells. ICP34.5 acts as a neurovirulence factor by recruiting protein phosphatase 1 (PP1) to dephosphorylate the alpha subunit of eukaryotic initiation factor 2 (eIF2-alpha) (Kambara et al., 2005). This action reverses the protein synthesis shutoff triggered by the host cell's double-stranded RNA-dependent protein kinase (PKR) response to viral infection. By restricting ICP34.5 expression to cells where the Nestin promoter is active—primarily glioma cells and neural stem cells—the virus can selectively replicate in and lyse tumor cells while remaining attenuated in mature, Nestin-negative neurons (Chiocca et al., 2020).